Sjogren's Syndrome

Meet the patient

A 52-year-old teacher arrives with two years of gritty, burning eyes she treats with drops bought over the counter, a mouth so dry she keeps water at the bedside to swallow a biscuit — the cracker sign, positive — and three new dental cavities in a year despite nothing else changing.[1]

She has bilateral, soft, recurrent parotid swelling, fatigue that floors her by three in the afternoon, and bloods showing an ESR of 68 with a CRP of 4. "I'm just getting old," she says. She is not; she has primary Sjogren's.[12]

Two questions decide her next decade, and they are the two every Sjogren's stem turns on: primary or secondary, and is an exclusion hiding? and is a lymphoma brewing in that parotid? Hold those two and the whole page slots into place.[1][2]

What Sjogren's is — and the one sentence that earns marks

It is autoimmune epithelitis, not "dry eyes and dry mouth". Lymphocytes infiltrate and progressively destroy the exocrine glands — chiefly the lacrimal and major salivary glands — producing the sicca syndrome of xerophthalmia and xerostomia. Because the glandular epithelium itself is the autoimmune target and an active participant, the modern name — autoimmune epithelitis — is the better one, and the one examiners reward.[1]

It is not confined to the glands. Extraglandular disease of skin, joints, lungs, kidneys, nerves and blood is variable but clinically important, and a characteristic predisposition to B-cell non-Hodgkin lymphoma shapes the whole follow-up.[1]

Two operational categories. Primary Sjogren's stands alone, classified by ACR/EULAR 2016. Secondary Sjogren's is sicca layered onto another connective-tissue disease — most often rheumatoid arthritis, then SLE and systemic sclerosis. The split matters for prognosis, criteria, lymphoma risk and the focus of therapy.[1]

Etymology for viva gold: sicca, Latin for "dry" — the sicca syndrome is literally the dry syndrome. Sjogren is Henrik Sjogren, the Swedish ophthalmologist who in 1933 tied keratoconjunctivitis sicca to arthritis. Mikulicz syndrome — bilateral painless salivary and lacrimal enlargement — was Jan Mikulicz-Radecki's eponym; most of what carried that label is now IgG4-related disease.[1]

Autoimmune epithelitis — why the gland is the target, not a bystander

The glandular epithelial cell is both victim and instigator. That single idea explains the disease, the name, and the biopsy. Stressed salivary and lacrimal epithelium releases its own nuclear antigens (the Ro52, Ro60 and La/SSB ribonucleoproteins), aberrantly expresses HLA class II, and secretes BAFF, IL-6 and IL-7. The gland stops being passive tissue and starts recruiting its own executioners.[1]

The defining lesion is focal lymphocytic sialadenitis — dense periductal aggregates of CD4-positive T-helper cells, B cells and plasma cells surrounding the ducts, with progressive acinar destruction and ductal narrowing. Function fails because surviving acini cannot secrete and narrowed ducts cannot deliver.[1]

The histological gold standard — and the test that earns three criteria points — is the focus score on minor (labial) salivary gland biopsy. A focus is a cluster of at least 50 mononuclear cells per 4 mm squared of glandular tissue; a focus score of at least 1 is diagnostic-grade for ACR/EULAR 2016. Ectopic germinal-centre-like structures in the glands predict the lymphoma that follows.[9]

The anti-Ro/SSA antibodies (Ro52/TRIM21 and Ro60) and anti-La/SSB are the serological signatures of this B-cell activation. They are not directly gland-toxic, but they define the disease, seed immune complexes, and — critically in pregnancy — cross the placenta to cause neonatal lupus and congenital heart block. Hypergammaglobulinaemia, rheumatoid-factor positivity (even without rheumatoid arthritis) and cryoglobulinaemia all reflect the same B-cell overdrive.[1]

The ACR/EULAR 2016 score — four points and you are in

The classification is a weighted score, and the weighting is the teaching point. The two strongest objective items — biopsy and anti-Ro — each carry three points; the three secretory tests each carry one. Reach four and primary Sjogren's is classified, provided no exclusion applies.[2]

The criteria apply to any patient with at least one symptom of ocular or oral dryness (or suspicion of SS from the ESSDAI questionnaire). Reproduce the items and their weights verbatim:[2]

• Labial salivary gland biopsy with focal lymphocytic sialadenitis and focus score at least 1 — 3 points
• Anti-SSA/Ro positive (anti-Ro52 and anti-Ro60 included) — 3 points
• Ocular staining score at least 5 (van Bijsterveld or SICCA/Oxford scheme) — 1 point
• Schirmer at most 5 mm in 5 minutes (at least one eye) — 1 point
• Unstimulated whole saliva flow at most 0.1 mL per minute (at most 1.5 mL in 15 minutes) — 1 point[2]

A total score of at least 4 classifies primary Sjogren's, provided no exclusion applies. Note that the 2016 criteria do not list rheumatoid arthritis or SLE as exclusions — they classify primary disease, so a patient with another defined connective-tissue disease is simply not classified as primary SS by these criteria; their sicca is labelled secondary.[2]

The classic trap: a 3-plus-1 score looks like a pass (3 from anti-Ro plus 1 from Schirmer) — and it is. But a patient who is anti-Ro negative can only reach 4 if the biopsy earns its 3 points; without the biopsy the score cannot cross the line. If anti-Ro is negative, the biopsy is not optional.[2]

The seven exclusions — screen before you classify, not after

Run the exclusion list before you run the score. Overlapping features or interference with the criteria tests make these absolute bars to a primary Sjogren's label:[2]

• Head and neck radiation treatment
• Active hepatitis C (HCV) infection
• AIDS (HIV)
• Sarcoidosis
• Amyloidosis
• Graft-versus-host disease (GVHD)
• IgG4-related disease[2]

Everyone forgets: HCV and HIV are not curiosities — both cause sicca and parotid swelling, both are formal exclusions, and a missed hepatitis C misdirects every decision that follows. Always send hepatitis B, hepatitis C and HIV serology before you classify.[1]

How common, who, and why the menopause matters

Sjogren's is the second most common systemic autoimmune rheumatic disease after rheumatoid arthritis — prevalence 0.1 to 0.6 percent of the general population, a 9 to 1 female-to-male ratio, and a peak onset at 40 to 60 years, clustering around the menopause. Declining oestrogen is not a coincidence; it is permissive and then, by its fall, a trigger of disease expression.[1][12]

[1] [12]

Risk factors to run on autopilot: female sex and oestrogen exposure; genetic susceptibility (HLA-DRB1*03, HLA-DR2 and HLA-DRw52, plus type I interferon-pathway polymorphisms IRF5 and STAT4); family history of autoimmunity; and viral triggers — Epstein-Barr, coxsackievirus, and (as an exclusion) hepatitis C. A north-south gradient is described, with southern European cohorts showing more extraglandular disease at presentation.[12]

The classic trap: men, the elderly and (rarely) children get Sjogren's too — and are under-diagnosed because nobody thinks of it. In a man with unexplained sicca, parotid swelling or distal renal tubular acidosis, the diagnosis is delayed by years. Raise the threshold of suspicion.[1]

Meet the patient at the bedside — sicca first, systemics second

The glandular core is universal; the extraglandular burden is the variable that decides severity. Most patients present with sicca; a minority present with a systemic feature — palpable purpura, distal RTA, a sensory neuropathy, recurrent dental caries or parotid swelling — and the sicca emerges only on direct questioning.[1]

Glandular (sicca) features

• Xerostomia — difficulty swallowing dry foods (she sips water to swallow a cracker), difficulty sustaining speech, altered taste, a furrowed or fissured tongue, rapid accelerated dental caries (often the earliest clue), recurrent oral candidiasis, sialadenitis.
• Xerophthalmia (keratoconjunctivitis sicca) — gritty, sandy or foreign-body sensation, burning, photophobia, paradoxical tearing, and the inability to cry emotionally. Untreated: keratitis, corneal abrasion, rarely perforation.
• Major salivary gland enlargement — bilateral, recurrent or persistent parotid and submandibular enlargement in roughly 30 to 50 percent over the disease course. Persistent, unilateral, hard or rapidly growing parotid enlargement is a red flag for lymphoma.[1]

Extraglandular (systemic) features

[1]

Neurological Sjogren's — pattern recognition examiners love. Three patterns recur. Sensory (small-fibre) neuropathy — burning distal extremities, normal conduction studies, reduced intra-epidermal nerve-fibre density on skin biopsy — is the commonest and most disabling. Trigeminal sensory neuropathy (often unilateral, numbness rather than pain) is relatively characteristic of Sjogren's. Sensorimotor neuropathy or mononeuritis multiplex signals vasculitic disease and warrants urgent immunosuppression. CNS disease is rarer and controversial; think transverse myelitis or optic neuritis, and screen for NMO-spectrum overlap.[1]

The differential — exclude before you classify

Sicca is common and nonspecific; the differential is wide and must be worked through. Run the exclusions hard, then the mimics. Each has a one-line discriminator.[1]

[1]

The discriminator line: for parotid swelling, the three questions are speed, sides and consistency — acute and bilateral with fever points to mumps or acute sialadenitis; meal-time and unilateral points to a stone; persistent, unilateral and hard points to lymphoma and demands biopsy.[1]

The dry-eye differential also includes meibomian gland dysfunction and chronic blepharitis, and the fatigue must be distinguished from depression, hypothyroidism (a co-existent autoimmune association), iron deficiency, sleep apnoea and fibromyalgia — all common in this demographic and frequently co-existing.[1]

The bedside round — look for systemics and lymphoma, not the diagnosis

Examination rarely delivers a diagnostic sign; its job is to find extraglandular disease and lymphoma red flags. Run it in this order.[1]

History — sicca onset, progression, diurnal pattern; medication review for anticholinergics; photosensitivity, Raynaud, joint pain and swelling; dental history (rapid caries, recurrent extractions); recurrent oral thrush; parotid swelling (intermittent or persistent, unilateral or bilateral); palpable purpura, neuropathic symptoms, dry cough; miscarriage or an offspring with congenital heart block (anti-Ro); and family history of autoimmunity. Quantify fatigue and dryness with the ESSPRI (EULAR Sjogren's Syndrome Patient Reported Index) — a 0 to 10 visual analogue scale across dryness, fatigue and limb pain.[4]

Bedside sicca examination — inspect the mouth for a dry, furrowed or fissured tongue, atrophic mucosa, candidiasis, caries and dental work; palpate the parotid and submandibular glands (size, tenderness, symmetry, consistency — hard, fixed or progressively enlarging glands are concerning); examine the eyes for conjunctival injection, corneal staining and a reduced tear meniscus. Demonstrate Schirmer's test: hook a standard filter-paper strip over the lower eyelid margin (lateral third) for 5 minutes with the eyes gently closed; at most 5 mm of wetting in at least one eye supports keratoconjunctivitis sicca.[1]

Extraglandular examination — palpate for palpable purpura on the lower limbs, assess for Raynaud and annular lesions, examine joints for non-erosive synovitis, listen for crackles of interstitial lung disease, examine the abdomen for hepatosplenomegaly, and screen neurologically for sensory neuropathy and trigeminal involvement. Check all cervical, axillary and inguinal nodes.[1]

Investigations that confirm and stage

No single test establishes primary Sjogren's. The diagnosis rests on the ACR/EULAR 2016 weighted score — objective histology, serology and secretory function integrated — with exclusions excluded.[2]

Autoantibody profile

• Anti-Ro/SSA — the key antibody, positive in roughly 60 to 95 percent of primary cases (most sensitive and most useful serology; 3 criteria points). Anti-Ro52 (TRIM21) and anti-Ro60 may be reported separately.
• Anti-La/SSB — positive in approximately 40 to 60 percent; more specific but less sensitive, and rarely positive without anti-Ro. Not in the weighted score but supports the diagnosis.
• ANA — frequently positive, often speckled.
• Rheumatoid factor — positive in roughly 40 to 60 percent, even without rheumatoid arthritis — a marker of B-cell hyperactivity.
• Anti-mitochondrial antibody — screen for primary biliary cholangitis overlap when liver enzymes are cholestatic.
• Cryoglobulins, complement (C3, C4) — cryoglobulinaemia and low C4 predict systemic vasculitis and lymphoma.[1]

General laboratory tests

• Full blood count — anaemia of chronic disease, leukopenia, lymphopenia, occasionally eosinophilia.
• ESR and CRP — the Sjogren split (below): ESR markedly elevated, CRP normal unless infection or active vasculitis.
• Immunoglobulins — polyclonal hypergammaglobulinaemia is typical; a falling IgG or IgM, or a monoclonal band, prompts lymphoma evaluation.
• Liver, renal function, urinalysis — screen for hepatic overlap, distal RTA (inappropriately high urine pH, metabolic acidosis) and tubular proteinuria.
• Hepatitis B, hepatitis C, HIV — always; these are exclusion criteria.[1]

Histology — labial (minor) salivary gland biopsy

A 3 to 5 mm incision on the lower inner lip yields 3 to 5 minor glands. Focal lymphocytic sialadenitis with a focus score of at least 1 is the histological gold standard (3 criteria points). Ectopic germinal-centre-like structures independently predict subsequent lymphoma. Biopsy is reserved for cases where anti-Ro is negative or systemic disease demands confirmation — it is not required when anti-Ro is positive and the score is already at least 4.[9]

Objective secretory tests

• Schirmer's test — at most 5 mm in 5 minutes (1 point).
• Ocular staining score — van Bijsterveld (rose Bengal) at least 4, or SICCA/Oxford at least 5 (1 point).
• Unstimulated whole saliva flow — at most 0.1 mL per minute, equivalent to at most 1.5 mL in 15 minutes (1 point).
• Salivary scintigraphy and sialography — older tests showing reduced uptake or excretion or punctate sialectasis; useful when criteria tests are equivocal but not part of the 2016 weighted score.
• Major salivary gland ultrasound — an emerging tool; parenchymal inhomogeneity, roundish hypoechoic areas, hyperechoic bands and cystic changes, scored on the Hocevar 0 to 48 scale. A normal ultrasound lowers the probability of primary SS; not part of the 2016 weighted score but a candidate for future revisions.[2]

Investigations for extraglandular disease

• Pulmonary function tests and high-resolution CT for interstitial lung disease.
• Nerve conduction studies and skin biopsy (small-fibre neuropathy) for neurological involvement.
• Renal function, arterial blood gas, urine pH for distal (type 1) RTA — high urine pH with metabolic acidosis and hypokalaemia is diagnostic.
• CT chest, abdomen and pelvis or PET-CT when lymphoma is suspected.[1]

The Sjogren split — ESR high, CRP normal

Examiners love this discordance, and juniors misread it every week. In active Sjogren's the ESR is often markedly elevated — driven by polyclonal hypergammaglobulinaemia, not by an acute-phase surge — while the CRP stays normal unless there is infection or active vasculitis. A rising CRP in apparent Sjogren's is therefore a signal to look for infection, vasculitis or lymphoma, not to assume a flare.[1]

The Sjogren split (named for the viva): ESR high, CRP normal means hypergammaglobulinaemia and inflammation, not infection. Hold that line and you will not reach for antibiotics in a patient whose "raised inflammatory markers" are simply immunoglobulins.[1]

Activity and damage measurement (EULAR tools)

The EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) and Patient Reported Index (ESSPRI) are the validated instruments for systemic activity and patient-reported burden respectively, used in trials and longitudinal care.[4]

Management — tears and saliva first, immunosuppression only for organs

Management is staged: symptoms first, then systemic therapy for organ-threatening disease. The EULAR 2020 recommendations and the supporting systematic review underpin this ladder.[3][11]

The hard truth that earns marks: no disease-modifying drug has been conclusively shown to improve sicca symptoms. Secretagogues and topical measures remain the backbone for glandular hypofunction; hydroxychloroquine, methotrexate and biologics are for the musculoskeletal and systemic burden, not for dryness itself.[11]

Foundation measures for all patients

• Meticulous oral hygiene — dental review every 3 to 6 months, topical fluoride (5000 ppm toothpaste), chlorhexidine or alcohol-free mouthwash, sugar-free diet, smoking cessation.
• Avoid anticholinergic drugs — tricyclics, antihistamines, opioids, diuretics, antispasmodics; review and switch where possible.
• Humidification of the bedroom, saline nasal sprays, vaginal lubricants for mucosal dryness.
• Vaccinate — pneumococcal, influenza, COVID-19, hepatitis B; screen and treat latent TB and hepatitis B and C before any biologic.[1]

Acute parotitis or suppurative sialadenitis

Treat with warm compresses, gland massage, sialogogues, hydration, and antistaphylococcal antibiotics — flucloxacillin 500 mg four times daily orally for 7 to 10 days, or amoxicillin-clavulanate. Recurrent or unilateral obstructive symptoms warrant imaging for a duct stone or stricture.[1]

Before escalating immunosuppression, always distinguish a disease flare from infection (fever, raised CRP, focal signs); investigate and treat infection first when unclear, because rituximab or cyclophosphamide during active infection can be catastrophic.[3]

Step 1 — Topical ocular and oral therapy (first line for sicca)

[1]

Step 2 — Secretagogues (muscarinic M3 agonists)

When topical measures are inadequate, oral secretagogues stimulate residual salivary and lacrimal secretion via the muscarinic M3 receptor.[11]

[1]

The classic trap: handing pilocarpine to a patient with asthma or narrow-angle glaucoma risks bronchospasm or acute angle-closure. The M3 agonist is the same receptor you are trying to stimulate for saliva and the same one you precipitate crises with — check the chest and the eye pressure first.[1]

Step 3 — Musculoskeletal and constitutional disease

• NSAIDs — naproxen 500 mg twice daily or ibuprofen 400 to 600 mg three times daily for arthralgia and mild arthritis.
• Hydroxychloroquine 200 to 400 mg daily (typically 200 mg twice daily, maximum 5 mg/kg/day) for fatigue, arthralgia and cutaneous disease, with annual retinal screening. The JOQUER trial did not show benefit on the primary sicca endpoint, but hydroxychloroquine is widely used and reasonable for musculoskeletal and skin disease.[5]
• Methotrexate 7.5 to 15 mg once weekly (with folic acid 5 mg weekly) or leflunomide 10 to 20 mg daily as steroid-sparing agents for persistent arthritis.
• A short course of low-dose prednisolone 5 to 10 mg daily, tapered over 2 to 4 weeks, is acceptable for flares; minimise long-term use.[3]

Step 4 — Immunosuppression for organ-threatening disease

[1]

Rituximab's place is nuanced. The TEARS randomised trial showed some improvement in fatigue and certain objective measures but did not meet its primary sicca endpoint; rituximab is therefore reserved for refractory systemic disease (vasculitis, cryoglobulinaemia, arthritis, severe parotid enlargement, neurological involvement) rather than for sicca itself.[6] Belimumab (anti-BAFF) showed signals of benefit in the BELISS open-label trial, particularly in early active disease.[7]

Step 5 — Organ-specific therapy

• Distal (type 1) renal tubular acidosis — oral sodium bicarbonate 1 to 2 g four times daily (or potassium citrate 10 mEq three times daily) titrated to serum bicarbonate at least 22 mmol/L, with potassium chloride replacement to correct hypokalaemia; prevents nephrocalcinosis, osteomalacia and hypokalaemic complications.
• Lymphoma — urgent haemato-oncology referral. Most low-grade MALT lymphomas of the salivary glands are indolent and may be observed or treated with localised rituximab or radiotherapy; high-grade transformation is treated with standard lymphoma protocols (R-CHOP).[8]

The organ-threatening extras — RTA, vasculitis, lung and nerve

Distal (type 1) renal tubular acidosis is the classic renal lesion. It causes hypokalaemia (occasionally periodic paralysis), nephrocalcinosis and osteomalacia. Less commonly, tubulointerstitial nephritis and — especially in cryoglobulinaemic disease — membranous or membranoproliferative glomerulonephritis occur. Diagnosis rests on metabolic acidosis with an inappropriately high urine pH (above 5.5) and a positive urinary anion gap; treatment is bicarbonate or citrate plus potassium replacement.[1]

Everyone forgets: the young woman with fatigue and intermittent weakness may have hypokalaemic periodic paralysis from undiagnosed distal RTA — and the cause is Sjogren's. Check the potassium, the venous bicarbonate and the urine pH before reaching for a neurological label.[1]

Cryoglobulinaemic or leucocytoclastic vasculitis presents as palpable purpura on the lower limbs, leg ulcers, mononeuritis multiplex or glomerulonephritis. Management combines immunosuppression (glucocorticoids with cyclophosphamide or rituximab) and, for severe cryoglobulinaemia, plasmapheresis.[3]

The lymphoma watch — five predictors

Salivary-gland MALT lymphoma is the hallmark malignancy of Sjogren's, with a lifetime incidence of roughly 5 to 10 percent and about a 16-fold increased relative risk of non-Hodgkin lymphoma versus the general population. Five clinical and serological predictors should prompt urgent haematology referral:[8]

[8]

Two histological markers complete the picture: ectopic germinal-centre formation on labial biopsy and a monoclonal gammopathy are independent risk markers and should lower the threshold for imaging and referral.[9]

The heart-block conversation — anti-Ro in pregnancy

Anti-Ro/SSA antibodies cross the placenta. They confer a roughly 1 to 2 percent risk of congenital heart block in a first pregnancy; the recurrence risk rises to 15 to 20 percent after one affected child. The conversation is non-negotiable and it starts at booking.[10]

Continue hydroxychloroquine through pregnancy — maternal use is associated with a reduced risk of recurrent cardiac manifestations of neonatal lupus. Monitor with serial fetal echocardiography from 16 to 26 weeks; if first- or second-degree block is detected, consider dexamethasone 4 mg daily (avoid fluorinated steroids unless myocarditis is present).[10]

Neonatal lupus rash and cytopenias are transient; third-degree (complete) heart block is irreversible and may require pacing. Avoid mycophenolate, methotrexate, cyclophosphamide and leflunomide in pregnancy; azathioprine is the preferred immunosuppressant if one is needed.[10]

Special populations

[1] [3] [10]

Primary versus secondary, in one paragraph

In secondary Sjogren's, the underlying connective-tissue disease drives therapy: rheumatoid arthritis (methotrexate or a TNF inhibitor or rituximab); SLE (hydroxychloroquine with immunosuppression for organ-threatening disease); systemic sclerosis (vasodilators, immunosuppression for ILD). Sicca measures are layered on top, and the disease is not separately classified.[3]

Complications and the preventable-harm list

[1]

The preventable-harm list — the recurring ways Sjogren's patients come to grief, and the cheap moves that stop it:[1]

• Attributing sicca to age or drugs and never investigating — especially in men and the elderly.
• Not screening for HCV and HIV — both are exclusion criteria, and a missed hepatitis C misdirects therapy.
• Failing to biopsy when anti-Ro is negative — without the biopsy score, classification is impossible.
• Missing the hypokalaemia of distal RTA — the young woman with fatigue and periodic paralysis may have undiagnosed Sjogren's.
• Attributing fatigue to depression or fibromyalgia while overlooking lymphoma, anaemia, hypothyroid overlap or active systemic disease.
• Giving unchecked pilocarpine in asthma or narrow-angle glaucoma — bronchospasm or acute angle-closure.
• Long-term glucocorticoids without bone protection, glycaemic monitoring, infection vigilance and PJP prophylaxis at high dose.
• Forgetting vaccination and live-vaccine avoidance on immunosuppression and biologics.[1]

Prognosis and disposition

Most patients run a stable, mild course for decades, and overall mortality is near-normal in unselected cohorts. Excess mortality is concentrated in those with systemic complications or lymphoma — the leading causes of excess death being lymphoma (the single largest contributor), systemic vasculitis and interstitial lung disease.[1]

The adverse prognostic markers — the high-risk profile — are low complement C4, cryoglobulinaemia, palpable purpura, persistent salivary gland enlargement, splenomegaly, lymphadenopathy, monoclonal gammopathy and a falling IgM or rheumatoid factor. These predict lymphoma and systemic activity and should lower the threshold for investigation and referral.[8][9]

Disposition is shared care: rheumatology and primary care jointly, with multidisciplinary referral as needed — ophthalmology (corneal disease, punctal plugs), dentistry and maxillofacial (caries prevention, biopsy, salivary ultrasound), haematology (suspected lymphoma), nephrology (RTA, glomerulonephritis), respiratory (ILD), neurology (neuropathy, myelitis) and obstetrics and maternal-fetal medicine (anti-Ro-positive pregnancy). Fatigue is frequently the most disabling symptom for quality of life even when objective disease is mild — patient education, exercise, cognitive-behavioural approaches and self-management are central.[1]

Monitoring and follow-up — review at least annually, more often if systemic disease is active or immunosuppression is in use. Each visit: focused history for new sicca, fatigue and systemic symptoms; oral and dental review (caries, candidiasis, parotid enlargement); eye assessment (corneal staining, tear break-up time); a search for lymphoma red flags (new parotid enlargement, lymphadenopathy, splenomegaly, weight loss); and baseline bloods — full blood count, ESR and CRP, renal and liver function, immunoglobulins, complement (C3, C4), cryoglobulins where indicated. A falling IgG or IgM, a monoclonal band, persistently low C4 or new glandular enlargement lowers the threshold for imaging and haematology referral.[1]

Evidence, guidelines and the names that score marks

Exam pearls — the marks are in these lines

• Sjogren's equals autoimmune epithelitis — the glandular epithelium is the target, not an innocent bystander.
• Anti-Ro/SSA is the key antibody — most sensitive, 3 criteria points, and the cause of neonatal lupus and congenital heart block in pregnancy. Anti-La/SSB is more specific but less sensitive and rarely positive without anti-Ro.
• Focus score (at least 50 mononuclear cells per 4 mm squared) on labial biopsy — the histological gold standard; focus score at least 1 earns 3 criteria points.
• Schirmer's test — at most 5 mm of wetting in 5 minutes supports keratoconjunctivitis sicca (1 point).
• ACR/EULAR 2016 — weighted score at least 4 (biopsy or anti-Ro equal 3 points each; ocular staining, Schirmer, saliva flow equal 1 each); excludes head and neck radiation, HCV, HIV, sarcoidosis, amyloidosis, GVHD, IgG4-RD.
• Secretagogues — pilocarpine 5 mg QID and cevimeline 30 mg TDS, muscarinic M3 agonists; contraindicated in asthma and narrow-angle glaucoma.
• ESR high but CRP normal — the Sjogren split; driven by polyclonal hypergammaglobulinaemia, not infection.
• Lymphoma (MALT, salivary gland) is the hallmark malignancy — 5 to 10 percent lifetime, 16-fold relative risk. Predictors: persistent parotid enlargement, low C4, cryoglobulins, palpable purpura, falling IgM or RF.
• Distal (type 1) renal tubular acidosis — hypokalaemia (occasionally periodic paralysis), nephrocalcinosis, osteomalacia; treat with bicarbonate and potassium.
• Anti-Ro in pregnancy — congenital heart block (1 to 2 percent, recurrence 15 to 20 percent); hydroxychloroquine reduces recurrence; fetal echo 16 to 26 weeks.
• HCV and HIV are exclusion criteria — always screen before classifying primary SS.
• No disease-modifying drug convincingly improves sicca — secretagogues and topical measures remain the backbone (JOQUER negative; TEARS sicca-endpoint negative).
• Fatigue is often the most disabling symptom for quality of life; do not dismiss it as psychological.
• EULAR tools — ESSDAI (clinician-assessed systemic activity, 12 domains), ESSPRI (patient-reported dryness, fatigue, limb pain).[1]

The mantra

Ro and the biopsy make four; tears and saliva first; immunosuppression only when an organ is at stake; never stop watching the parotid.[1][2][8]

Consultant confession: the mistake I made as a registrar was treating the dry mouth and forgetting the parotid. The sicca is what the patient complains of; the parotid is what kills them. Every annual review, I palpate the parotid and the nodes, check the C4 and the IgM trend, and ask about weight loss — because a MALT lymphoma caught early is observed, and one caught late is R-CHOP.[8][9]

Ward-round test — four stems, sixty seconds each

Stem 1 — the teacher from the vignette (answer)

Two years of gritty eyes, water at the bedside to swallow a biscuit, three new cavities, bilateral parotid swelling, fatigue, and an ESR of 68 with a CRP of 4. First investigation, first treatment, and the one thing you must not forget? Model: First investigation: anti-Ro/SSA plus Schirmer's test and unstimulated saliva flow (you can score her at the first visit), with hepatitis B, C and HIV sent in parallel because they are exclusions. First treatment: preservative-free artificial tears, saliva substitutes and fluoride, then a secretagogue (pilocarpine 5 mg QID) once asthma and glaucoma are excluded — checking the chest and eye pressure first because M3 agonism causes bronchospasm and angle-closure. The one thing you must not forget: palpate the parotids and the nodes and trend the C4 and IgM every visit — her bilateral soft parotid swelling is common, but persistence, unilateral hardening or new adenopathy is a MALT lymphoma until proven otherwise.[1][2][8]

Stem 2 — anti-Ro negative, Schirmer positive, score 1 (answer)

A 49-year-old with sicca, a Schirmer of 3 mm and negative anti-Ro and anti-La. Biopsy not yet done. Can you classify primary Sjogren's, and what is the next move? Model: Not yet — her score is 1 (Schirmer only), and anti-Ro-negative disease can only reach 4 if the labial biopsy earns its 3 points (biopsy 3 plus Schirmer 1 plus one more secretory test 1 is the route). The next move is a labial (minor) salivary gland biopsy for the focus score, ocular staining, and unstimulated saliva flow. Re-check exclusions (HCV, HIV) while you wait. Do not label her drug-induced or age-related without objective testing — that is the classic trap.[2][9]

Stem 3 — weakness, potassium 2.4, ESR high (answer)

A 38-year-old woman with Sjogren's presents with proximal leg weakness, a potassium of 2.4 mmol/L, venous bicarbonate 16, and a urine pH of 6.5. What is this, and what do you give? Model: Distal (type 1) renal tubular acidosis — metabolic acidosis with an inappropriately alkaline urine (pH above 5.5) and hypokalaemia, occasionally presenting as periodic paralysis. Give oral sodium bicarbonate 1 to 2 g four times daily titrated to bicarbonate at least 22, and potassium chloride replacement. This is the classic renal lesion of Sjogren's, and the hypokalaemia is the dangerous part — correct it carefully. This is the 'everyone forgets' moment: unexplained hypokalaemic weakness in a young woman is Sjogren's until excluded.[1]

Stem 4 — anti-Ro positive and pregnant (answer)

A 31-year-old with primary Sjogren's, anti-Ro positive, is at 8 weeks' gestation, her first pregnancy. What do you counsel, change and monitor? Model: Counsel on the 1 to 2 percent risk of congenital heart block and the 15 to 20 percent recurrence after an affected child — she has no prior affected child, so the baseline risk applies. Continue hydroxychloroquine through pregnancy — it is associated with reduced recurrence of cardiac neonatal lupus. Arrange serial fetal echocardiography from 16 to 26 weeks; if first- or second-degree block appears, consider dexamethasone. Switch any teratogenic immunosuppressant to azathioprine if one is needed (avoid mycophenolate, methotrexate, cyclophosphamide, leflunomide). Third-degree block is irreversible and may need pacing; neonatal rash and cytopenias are transient.[10]

References

1. [1]Mariette X, Criswell LA. Primary Sjögren's Syndrome N Engl J Med, 2018.PMID 29514034
2. [2]Shiboski CH, Shiboski SC, Seror R, Criswell LA, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts Arthritis Rheumatol, 2017.PMID 27785888
3. [3]Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies Ann Rheum Dis, 2020.PMID 31672775
4. [4]Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI) Ann Rheum Dis, 2015.PMID 24442883
5. [5]Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial JAMA, 2014.PMID 25027140
6. [6]Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial Arthritis Rheum, 2010.PMID 20131246
7. [7]Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study Ann Rheum Dis, 2015.PMID 24347569
8. [8]Nocturne G, Mariette X Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management Br J Haematol, 2015.PMID 25316606
9. [9]Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjögren's syndrome Ann Rheum Dis, 2011.PMID 21715359
10. [10]Izmirly P, Kim M, Friedman DM, et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers J Am Coll Cardiol, 2020.PMID 32674792
11. [11]Brito-Zerón P, Retamozo S, Kostov B, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome RMD Open, 2019.PMID 31749986
12. [12]Brito-Zerón P, Acar-Denizli N, Ng WF, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome Rheumatology (Oxford), 2020.PMID 31873754